Avalo Therapeutics (NASDAQ:AVTX) Trading 9.6% Higher – Time to Buy?

Avalo Therapeutics, Inc. (NASDAQ:AVTX) shares traded up 9.6% during trading on Monday . The company traded as high as $15.81 and last traded at $16.1050. 92,993 shares were traded during trading, a decline of 92% from the average session volume of 1,135,265 shares. The stock had previously closed at $14.70.

Analyst Ratings Changes

Several research firms recently issued reports on AVTX. Wall Street Zen raised Avalo Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Sunday, March 29th. Citizens Jmp decreased their target price on Avalo Therapeutics from $62.00 to $55.00 and set a “market outperform” rating on the stock in a research note on Thursday, May 14th. BTIG Research reaffirmed a “buy” rating and issued a $58.00 price target on shares of Avalo Therapeutics in a report on Tuesday, June 16th. Weiss Ratings upgraded Avalo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 15th. Finally, Bank of America initiated coverage on Avalo Therapeutics in a report on Friday, June 12th. They set a “buy” rating and a $35.00 price objective for the company. Twelve research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $46.67.

Avalo Therapeutics Trading Up 14.1%

The business’s fifty day moving average price is $15.51 and its 200-day moving average price is $16.07. The company has a market capitalization of $881.70 million, a P/E ratio of -3.08 and a beta of 0.83.

Avalo Therapeutics (NASDAQ:AVTX) last released its earnings results on Wednesday, May 13th. The company reported ($0.98) EPS for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.02. As a group, equities research analysts forecast that Avalo Therapeutics, Inc. will post -2.58 EPS for the current year.

Insider Buying and Selling

In other Avalo Therapeutics news, insider Mittie Doyle sold 3,970 shares of the company’s stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $18.01, for a total value of $71,499.70. Following the completion of the sale, the insider owned 3,622 shares of the company’s stock, valued at $65,232.22. This represents a 52.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Paul Varki sold 75,063 shares of Avalo Therapeutics stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $20.17, for a total transaction of $1,514,020.71. Following the transaction, the insider directly owned 3,634 shares in the company, valued at $73,297.78. This trade represents a 95.38% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 112,586 shares of company stock worth $2,089,651 in the last quarter. 4.46% of the stock is owned by insiders.

Institutional Trading of Avalo Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Orbimed Advisors LLC increased its holdings in shares of Avalo Therapeutics by 39.5% in the third quarter. Orbimed Advisors LLC now owns 1,349,300 shares of the company’s stock worth $17,150,000 after buying an additional 382,300 shares during the period. Affinity Asset Advisors LLC boosted its holdings in Avalo Therapeutics by 27.6% during the 1st quarter. Affinity Asset Advisors LLC now owns 1,340,840 shares of the company’s stock valued at $20,019,000 after acquiring an additional 289,786 shares during the period. Nantahala Capital Management LLC grew its position in Avalo Therapeutics by 24.1% during the 3rd quarter. Nantahala Capital Management LLC now owns 1,235,000 shares of the company’s stock worth $15,697,000 after acquiring an additional 240,000 shares during the last quarter. Caligan Partners LP grew its position in Avalo Therapeutics by 5.8% during the 4th quarter. Caligan Partners LP now owns 881,533 shares of the company’s stock worth $16,009,000 after acquiring an additional 48,200 shares during the last quarter. Finally, Balyasny Asset Management L.P. purchased a new position in Avalo Therapeutics in the 3rd quarter worth approximately $10,390,000. 87.06% of the stock is owned by institutional investors.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.